Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PDUFA V Agreement Set In Four Areas, But Broad FDA/Industry Talks Continue

Executive Summary

FDA and industry have reached agreement on four issues in the Prescription Drug User Fee Act reauthorization, including adjustments to risk-benefit policy and creation of a meta-analysis team.
Advertisement

Related Content

PhRMA Testing Pilot Framework For Structured Benefit-Risk Assessment
FDA, CMS To Standardize Regulatory Analytical Tools
Orphan Drugs Need Easier, Speedier Approval, Not More Exclusivity, CEO Says
PDUFA Needs Mid-Cycle Correction System As Part Of Reauthorization, Industry Says
Orphan Drugs Warrant Flexibility On Clinical Pharmacology Data, FDA Panel Says
Does The Orphan Drug Act Need A Facelift? Advocates Consider Changes
User Fee Waivers For Small Businesses Might Get Smaller Under PDUFA V
NDA Review Pilot Will Be Mandatory, Assuming Program Flies At All
NDA Review Pilot Will Be Mandatory, Assuming Program Flies At All
"Mega-UFA" Is Behind Schedule; Combined User Fee Bill Will Be Difficult, But Still Expected

Topics

Advertisement
UsernamePublicRestriction

Register

PS053190

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel